Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem (GB:0LOV)
LSE:0LOV
Holding GB:0LOV?
Track your performance easily
0LOV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.14 - $13.94
Previous Close$3.97
Volume2.93K
Average Volume (3M)4.93K
Market Cap
$173.58M
Enterprise Value$101.83M
Total Cash (Recent Filing)$113.17M
Total Debt (Recent Filing)$41.43M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Mar 18, 2025EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding44,506,526
10 Day Avg. Volume1,387
30 Day Avg. Volume4,930
Standard Deviation0.26
R-Squared0.00115
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)18.51
Price to Sales (P/S)17.36
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.18
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$11.38Price Target Upside186.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Verastem News
PremiumCompany Announcements
Verastem Inc. Reports Increased Operating Expenses and Net Loss
Bulls Say, Bears Say
Bulls Say
Market ExpansionKRAS G12C NSCLC represents a much larger indication for the company compared to LGSOC and could become an exciting expansion opportunity with positive results from RAMP 203.
Stock PerformanceThe updated price target implies a 100% upside potential for Verastem Inc's stock.
Treatment AdvancementsThe combination of avutometinib and defactinib has shown a 31% overall response rate and 12.9 months progression-free survival, representing a significant improvement over current treatments.
Bears Say
Market DecisionVSTM shares experienced a significant drop due to the decision to initially seek approval only for KRAS-mutant patients, not including KRAS-wild-type patients.
Regulatory UpdateVerastem Inc shares fell 20% due to market disappointment over a regulatory update limiting initial approval to a subset of patients.
Stock ValuationThe stock is still trading at near-cash levels with little value to a program that has the potential for an accelerated approval in 2025.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.05% Insiders
5.53% Mutual Funds
43.24% Other Institutional Investors
42.64% Public Companies and
Individual Investors
0LOV FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $2.14 and its highest was $13.94 in the past 12 months.
What is Verastem’s market cap?
Currently, no data Available
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 18, 2025 which is in 82 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 06, 2024. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.738 by $0.138.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -$0.81.
How many shares outstanding does Verastem have?
Verastem has 44,506,527 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.738. Following the earnings report the stock price went down -9.564%.
Which hedge fund is a major shareholder of Verastem?
Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at N/A.
---
Verastem Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.38 (186.72% Upside)
$11.38 (186.72% Upside)
Blogger Sentiment
Bullish
GB:0LOV Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $11.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.78%
12-Months-Change
Fundamentals
Return on Equity
-136.87%
Trailing 12-Months
Asset Growth
-28.26%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
0LOV Stock 12 Month Forecast
Average Price Target
$11.38
▲(186.72% Upside)
Technical Analysis
Verastem
―
Adaptimmune Therapeutics
―
Moleculin Biotech
―
Cellectar Biosciences
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering 0LOV
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+0.13%
reiterated a buy rating 2 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +0.13% per trade.
---